The combined market for asthma, COPD and allergic rhinitis drugs is expected to decline slightly to $42.0bn between 2010 and 2016. Patent expiries combined with a tough regulatory environment are the key market resistors.
The Asthma, COPD & Allergic Rhinitis Market Outlook to eBook Free
